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transplants were 6/10 or higher match. 56 (52%) patients
were transplanted in CR1/PR1, 39 (36%) had stable disease or
<PR and 13 (12%) had resistant or refractory disease. The
CMV status was 26 (25%) D-/R-; 40 (39%) D-/R+, 5 (5%) D+/R-
and 32 (31%) D+/R+. 61 (56%) patients received ABO
compatible transplant, 26 (24%) had a minor incompatibility
and 22 (20%) had a major incompatibility.
The major ABO incompatibility group showed a trend
towards inferior survival compared to both ABO compatible
or minor ABO incompatible transplants. When evaluating
conditioning regimens separately similar trend was seen
among MA, NMA and RIC transplants, but did not reach
statistical signiﬁcance.
No difference was seen in the following factors: gender,
age at SCT, CMV status, acute or chronic GVHD.
Conclusion: In our experience, the use of a major ABO
incompatible donor may represent a risk factor for outcome
of ALLOSCT. Analysis of a larger cohort of patients may pro-
vide further understanding of the impact of ABO compati-
bility on ALLOSCT outcome.333
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Mismatched Related Haplo e Identical SCT
UPN 11/2488 13/0765
Age(y)/ sex 29 / M 30 / M
Diagnosis Relapsed AML CML - AP
Disease status Progressive diseases Progressive disease
Donor Sister Brother
Age (y)/sex 33 / F 33 / M
Stem cell CD34+/kg 5.88 x 106 5.6 x 106
MNC/kg 4.33 x 108 5.3 x 108
engraftment D+14 D +17
Mucositis Gr II Gr III/ IV
GVHD - Gr I
Stay length 47 days 38 days
D+28 chimerism 100% 100%
status Alive +395 Died +60 DAHTransplant, Tata Medical Center, Kolkata, India; 2 Clinical
Haematology & Bone Marrow Transplant, TMC, Kolkata, India;
3 Tata medical Center, Kolkata, India; 4 Clinical Haematology,
Tata Medical Center, Kolkata, India; 5 Clinical Hematology &
Bone Marrow Transplant, Apollo Hospital, Bangalore, India;
6 BMT Nursing, Tata medical Center, Kolkata, India
Five patients with progressive disease were transplanted
using the John’s Hopkins protocol but with IV busulphan
3.2mg/kg/day x 4 days given along with ﬂudarabine. The
donors were all siblings and the graft was peripheral blood
stem cells harvested after 4 days of G-CSF. Table I gives the
details of these patients.
All patients had progressive disease and the patient with
AML in ﬁrst relapse with 30% blasts at the time of transplant
(UPN 11/2488) is now one year post transplant with 100%
donor chimerism and no graft versus host disease.. The
protocol is well tolerated with rapid engraftment ( day +14-
17), a very low incidence of mucositits and no VOD. One
patient with CML and earlier blast transformation who had
received multiple rounds of chemotherapy and was in
accelerated phase at the time of transplant died of respira-
tory failure with a presumptive diagnosis of Diffuse Alveolar
Haemorrhage which could be related to busulphan. The pa-
tient with progressive NK T cell lymphoma who had failed
CHOP, and SMILE rejected his graft after achieving full donor
chimerism and succumbed to sepsis with multi-organ failure
while pancytopenic.
The addition of myelablationwith IV busulphan to the John’s
Hopkins protocol of PT-Cy is feasible and may reduce the
frequency of relapse.334
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D +15 - D +14
Gr I Gr IV Gr III
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Alive +60 Died Alive
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to success after reduced intensity conditioning (RIC) alloge-
neic hematopoietic stem cell transplantation (HSCT) for pa-
tients with acute leukemia and MDS. The ideal RIC regimen
has not been deﬁned. Clofarabine is a nucleoside analogue
with potent anti-leukemia activity and its inclusion in RIC
HSCT could potentially lead to decreased rates of disease
relapse.
Methods: We conducted a phase II clinical trial of reduced
intensity busulfan (6.4 mg/kg IV total) with clofarabine (40
mg/m2 IV daily x 4 days) conditioning before allogeneic 8/8
HLA-matched related or unrelated donor HSCT. GVHD pro-
phylaxis was with tacrolimus and methotrexate (5 mg/m2 on
days 1, 3, 6). The primary endpoint was donor neutrophil
engraftment by day +40 after HSCT. Secondary endpoints
included non-relapse mortality, rates of acute and chronic
GVHD, PFS, and OS.
Results: 34 patients with AML (n¼24), MDS (n¼6), and ALL
(n¼4) were enrolled and underwent RIC HSCT. Patients with
AML or ALL were in CR and patients with MDS had < 10%
bone marrow blasts. The median age of patients was 63.5
(range 25, 74) and median HCT-CI score was 1 (range 0, 9).
Engraftment with donor chimerism by day +40 was achieved
in 33 of 34 patients with one patient dying before successful
count recovery. Of the patients who engrafted and had
chimerism data available (n¼30), median donor chimerism
measured at approximately day +30 after HSCT was 97%
(range 85%, 100%) for all leukocytes and median 80% (50%,
100%) for the CD3+ population. Of those who have been fol-
lowed for at least 100 days after HSCT (n¼28), the probability
of NRM at day 100 was 6.4% and 1-year was 36% (95% CI, 15%,
57%). Causes of NRM included acute GVHD (n¼4), infection
(n¼2), and multi-organ failure (n¼2). Four of the six patients
with MDS died of NRM, all of whomwere older than 65 and
had HCT-CI scores 4 or above. The other two non-relapse
deaths were due to acute GVHD in the setting of early taper
of tacrolimus, one for decreasing chimerism and the other for
neurological complications. There were no cases of hepatic
VOD. The 12-month cumulative incidence of disease relapse
was 27% (95% CI, 12%, 44%). The 6-month cumulative inci-
dence of acute GVHD was 35% (95% CI, 18%, 53%) and the 12-
month cumulative incidence of chronic GVHD was 24% (95%
CI, 9.2%, 43%). The 12-month probability of PFS was 38% (95%
CI, 18%, 59%) and OS was 41% (95% CI, 19%, 62%).
Conclusion: Reduced intensity conditioning with busulfan
and clofarabine engenders successful donor engraftment
with acceptable rates of toxicity, NRM, and GVHD, although
caution should be used in older patients with signiﬁcant
comorbidities. Longer follow-up and comparison of out-
comes with ﬂudarabine-based regimens will be important in
deﬁning the role of this RIC regimen.335
The Impact of Mold Infections after Allogeneic
Transplantation
Tracey L. Churay, Holly A. Justman, Nancy L. Skurka,
Steven C. Goldstein, Attaphol Pawarode, John Magenau,
Daniel R. Couriel. Adult Blood and Marrow Transplant
Program, University of Michigan, Ann Arbor, MI
Introduction: Fungi are among the most common microbes
encountered by mammalian hosts and a major cause of
morbidity and mortality of allogeneic hematopoietic stem
cell transplantation (HSCT). Both innate and adaptive im-
munity prevent invasive fungal infections (IFI), and are
impaired after HSCT. Due to Candida prophylaxis, Aspergillus
and other molds are emerging as one of the main causes ofnon-relapse mortality (NRM) after allogeneic HSCT. In this
study, we retrospectively evaluated the incidence of IFI and
their impact on the outcomes of allogeneic HSCT.
Methods: The data was obtained from University of Michi-
gan Blood and Marrow Transplant Program database under
an IRB-approved protocol. We included only proven and
probable fungal infections, deﬁned according EORTC/MSG
criteria (CID 2008; June 15;46 (12):1813).
Results: A total of 50 IFI were diagnosed in 542 patients
between 2007 and 2012, 76% (n¼37) due to mold mostly
represented by Aspergillus (n¼24, 63%), followed by Zygo-
myces and Rhizopus. Only 3/37 infections were diagnosed in
2012, probably reﬂecting more consistent prophylaxis
against mold during this period. The CI of mold infections
was 6.6% (95% CI 5-10%) and 10.4% (95% CI 8-14%) at 1 and 2
years respectively, with a median time to infection of 194
days (9-644). The median prednisone dose was 15 mg at the
time of diagnosis, with a median duration of therapy of 124
days (0-1757). Mold infections were signiﬁcantly more
common in patients with a history of acute GVHD (aGVHD, CI
at 1y 10.3% vs. 0.2%, HR¼6.2, p¼0.0001), but not in those
with chronic GVHD (cGVHD, CI at 1y 5.4 vs. 7.7%, HR¼0.7,
p¼0.2). The case fatality rate of mold infections was high at
83.3%, and they were associated with a substantial increase
in NRM both in aGVHD (70 vs. 34% at 2 ys, HR¼2.6, 1.68-4.1)
and cGVHD (43% vs. 15% at 2y, HR¼4, 2.2-7.5). After adjusting
for other HSCT-related factors, mold infections persisted as
an independent risk factor for NRM for patients with both
aGVHD (HR¼2.78, 1.7-4.4) and cGVHD (HR¼4, 2-7).
Conclusions: Mold infections are emerging as a major cause
of infection-related mortality, with a very high case fatality
rate and a signiﬁcant impact on NRM in patients with aGVHD
and cGVHD. Our data further supports the need for anti-mold
prophylaxis in high-risk populations.336
Early Human Herpesvirus Type 6 Reactivation in
Umbilical Cord Blood Allogeneic Stem Cell
Transplantation
Frank Cirrone 1, Cindy Ippoliti 2, Koen van Besien 3. 1 Pharmacy,
NewYork-Presbyterian Hospital, New York, NY; 2 Pharmacy,
NYP/Cornell, NY, NY; 3 University of Chicago, Chicago, IL
Human Herpesvirus Type 6 (HHV-6) reactivation occurs in
38%-67% of hematopoietic stem cell transplant (HSCT) re-
cipients eusually within the ﬁrst month post-transplant.
Studies have shown that HHV-6 reactivation after allogeneic
HSCT delays engraftment, has myelosuppressive effects, and
potentially increases the risk of developing acute graft-
versus-host disease (aGVHD). An increased incidence of
HHV-6 reactivation in umbilical cord blood (UCB) HSCTs has
been previously described.
In June 2012, Weill Cornell Medical Center began performing
allogeneic HSCTs with haploidentical stem cells followed by
UCB (Haplo-Cord). No published studies have examined
HHV-6 reactivation and its sequelae in Haplo-Cord HSCTs.
The purpose of this study was to retrospectively assess for
risk factors and sequelae of HHV-6 reactivation in UCBHSCTs.
The objectives were to determine the impact of early HHV-6
reactivation (within 60 days of transplant) on overall survival
and incidence of aGVHD at 100 days post-transplantation.
Fifty-seven adult transplants between August 2010 and June
2013 utilizing UCB with  1 HHV-6 PCR level reported were
included: 29 double UCB HSCTs, 26 Haplo-Cord HSCTs, and 2
single UCB HSCTs.
HHV-6 reactivation occurred in 35/57 (61.4%). No baseline
factors (age, ASBMT RFI disease classiﬁcation, conditioning
